Add Your Heading Text Here

hippocrates research

published paper

Hippocrates Research is frequently involved in high profile projects and 60+ of them have been published in international scientific journals, including 4 papers in the New England Journal of Medicine.

In the last 5 years results of at least 5-6 projects per year have been published in international journals.

2010
2011
2012
2013
2014
2015

3 publications

3 publications

5 publications

1 publication

4 publications

3 publications

2016
2017
2018
2019
2020

6 publications

5 publications

13 publications

6 publications

10 publications

  • Falconi M, Fazio N, Ferone D, Versari A. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Journal: Expert Opinion on Pharmacotherapy. Published online: 29 Sep 2020.
  • Saccarello A, Montarsolo P, Massardo I, Picciotto R, Pedemonte A, Castagnaro R, Brasesco PC, Guida V, Picco P, Fioravanti P, Montisci R, Schiavetti I, Vanelli A. Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Prim Care Companion CNS Disord 2020;22(0):19m02578.
  • Samama M, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, Fisher W, Martínez-Martín J, Duverger D, Deygas B, Presles E, Cucherat M, Mismetti P for the PRONOMOS Investigator. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med. 2020 Mar 29.
  • Fioravanti P., Champiot M, Vaccari D, Besio E, Montisci R. Trends in clinical research on and with Software as Medical Devices (SaMD). ICPM/SIMeF conference, Rome 25-27 March 2020.
  • Fioravanti P., Champiot M, Zurita R, Mascagni P, Vacccari D. Profile of the protocols of interventional studies using Software as Medical Devices (SaMD). ICPM/SIMeF conference, Rome 25-27 March 2020.
  • Fioravanti P, Vaccari D, Consiglieri C, Pincin C, Besio E. Smoking cessation: clinical development of dedicated SaMDs (Software as Medical Devices). ICPM/SIMeF conference, Rome 25-27 March 2020.
  • Salaffi, S. Farah, M. Di Carlo, L. Sinigaglia, M. Galeazzi, R. Gerli, M. Sonnati, V. Giorgi, P. Sarzi-Puttini on behalf of the Italian Society of Rheumatology (SIR), M. Masullo on behalf of the Ministero della Salute – Direzione Generale della Programmazione Sanitaria, Roma, Italy. The Italian Fibromyalgia Registry: a new way of using routine real-world data concerning patient-reported disease status in healthcare research and clinical practice. Clin Exp Rheumatol 2020; 38 (Suppl. 123).
  • Tagliaferri, J. Oldenburg, K. Peerlinck, G. Castaman. Real‐world Use of Recombinant Factor IX Albumin Fusion Protein (rIX‐FP) in Patients with Hemophilia B: A Multinational Prospective, Non‐interventional, Post‐marketing Surveillance Study. Res Pract Thromb Haemost. 2019;3(Suppl. 1):1–891 [Abstracts of the XXVII Congress of the International Society on Thrombosis and Haemostasis. PB0281].
  • De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord. 2019 Jul 12;19(1):165.
  • Marchesoni A, D’Angelo S, Anzidei M, Bortolotti R, Cantini F, Caramella D, Carotti M, Chimenti M, Delle Sedie A, Egan CG, Fabbroni M, Frediani B, Fusaro E, Galeazzi M, Gallazzi MB, Gentileschi S, Gentili F, Gerli R1 Gilio M, Iannone F, La Paglia E, Lubrano E, Macarini L, Olivieri I, Pellerito R, Ramonda R, Salvarani C, Scarano E, Scarpa R, Spaggiari L, Spanò A, Zawaideh JP, Mazzei MA; SHARE Study Group. Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):575-584.
  • Kwan P. Commentary on “Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?” Epilepsia. 2019 Jun;60(6):1124-1125.
  • De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104.
  • Zaccara G, Mula M, Ferrò B, Consoli D, Elia M, Giallonardo AT, Iudice A, La Neve A, Meletti S, Tinuper P, Zummo L, Perucca E. Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy? Epilepsia. 2019 Jan;60(1):175-183.
  • Remitz A, De Pità O, Mota A, Serra-Baldrich E, Vakirlis E, Kapp A. Position statement: topical calcineurin inhibitors in atopic dermatitis. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2074-2082.
  • Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy – A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018 Nov 1;270:160-166.
  • Olivieri I, Accorinti M, Abicca I, Bisceglia P, Cimino L, Latanza L, Leccese P, Lubrano E, Marchesoni A, Miserocchi E, Neri P, Salvarani C, Scarpa R, D’Angelo S; CORE Study Group. Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. Rheumatol Int. 2018 Sep;38(9):1727-1734.
  • Verze P, Arcaniolo D. Imbimbo C, Cai T, Venturino L, Spirito L, Califano G, La Rocca R, Mirone V. General and sex profile of women with partner affected by premature ejaculation: results of a large observational, non-interventional, cross-sectional, epidemiological study (IPER-F).. Andrology. 2018 Sep;6(5):714-719.
  • Colonna P, von Heymann C, Santamaria A, Matsushita Y, Unverdorben M. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design. Clin Cardiol. 2018:1-7.
  • Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF – HF substudy. Int J Cardiol. 2018 Aug 15;265:141-147.
  • Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thromb J. 2018 May 31;16:18.
  • Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Castro DJ, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thromb J. 2018 May 1;16:9.
  • Verze P, Arcaniolo D, Palmieri A, Cai T, La Rocca R, Franco M, Venturino L, De Sio M, Mirone V. Premature Ejaculation Among Italian Men: Prevalence and Clinical Correlates From an Observational, Non-Interventional, Cross-Sectional, Epidemiological Study (IPER). Sex Med. 2018 May 23.
  • Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D’Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Adv Ther. 2018 Apr;35(4):545-562.
  • Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P. Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. 2018 Mar 17.
  • Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, Varano M, Sivaprasad S, Eleftheriadis H, Menon G, Amaro M, Ayello Scheer S, Creuzot-Garcher C, Nascimento J, Alves D, Nunes S, Lobo C, Cunha-Vaz J; EVICR.net Study Group. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). 2018 May;125(5):691-700.
  • De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis. 2018 Feb;111(2):74-84
  • Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017 Sep;157:181-188.
  • Franchi C, Miracapillo A, Narcisi A, Zichichi L. Therapeutic adherence in mild-to-moderate psoriasis: practical indications by a Delphi Panel.. Therapy perspectives 2017 Sep. Year XX, N. 13.
  • Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017 Jul 23;6(7)
  • Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, PREFER in VTE Scientific Steering Committee And The Prefer In Vte Investigators OBOT. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost. 2017 Jun 27;117(7):1326-1337.
  • Antonini A, Barone P, Bonuccelli U et al. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):317-324.
  • Renda G, Patti G, Sangiuolo R, Attena E, Malpezzi MG, De Caterina R; a nome dello Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry. G Ital Cardiol (Rome). 2016 Nov;17(11):922-931
  • Epis OM, Casu C, Belloli L et al. Pixel or Paper? Validation of a Mobile Technology for Collecting Patient-Reported Outcomes in Rheumatoid Arthritis. JMIR Res Protoc. 2016 Nov 16;5(4):e219.
  • Ricci E. The management of chronic ulcers with an acidoxidising solution. J Wound Care. 2016 Aug;25(8):443-50.
  • Ardizzone S, Bevivino G, Monteleone G. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn’s disease. Therap Adv Gastroenterol. 2016 Jul;9(4):527-32.
  • Monteleone G, Di Sabatino A, Ardizzone S, Pallone F, Usiskin K, Zhan X, Rossiter G, Neurath MF. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn’s disease. Aliment Pharmacol Ther. 2016 Mar;43(6):717-24.
  • Prantera C. Orchard T. Prevalence of Extraintestinal manifestations in Inflammatory Bowel Disease in Italy: The ISPEM study. CPT Orchard – Researchgate.net (Oct 2015).
  • Frisinghelli A, Cesana F, Clavario P et al. Italian cardiologists and tobacco smoking. A survey on the prevalence and knowledge of smoking and strategies for smoking cessation in a cohort of Italian cardiologists. G Ital Cardiol 2015;16: 426-432.
  • Monteleone G, Neurath MF, Ardizzone S et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015 Mar 19;372(12):1104-13.
  • De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P; PREFER in AF Registry Investigators. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014 Oct;100(20):1625-35.
  • Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 Sep 4;371(10):895-905.
  • Barabino S, Rolando M, Nardi M, Bonini S, Aragona P, Traverso CE. The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye. Eur J Ophthalmol. 2014 Mar-Apr;24(2):173-8.
  • De Caterina R, Renda G, Sangiuolo R, Attena E, Di Lecce L, Romeo F; Steering Committee del Registro Europeo PREFER in AF. Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry. G Ital Cardiol (Rome). 2014 Feb;15(2):99-109.
  • Certan D, Righini V, Oliva M et al. Bioavailability of l-thyroxine and its metabolites after topical treatment with an emulsion containing 0.1% micronised l-thyroxine. G Ital Dermatol Venereol. 2013 Jun;148(3):287-92.
  • Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
  • Monteleone G, Fantini MC, Onali S et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012 Apr;20(4):870-61.
  • Fiocchi A, Omboni S, Mora R, Macchi A, Nespoli L, Arrigoni S, Guastini L, Castelnuovo P, Graziani D, Marcassa S. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children. Allergy Asthma Proc. 2012 Mar-Apr;33(2):197-204
  • Zaim M, Piselli L, Fioravanti P et al. Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial. Eur J Nutr. 2012 Mar;51(2):221-9.
  • Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect. 2012 Feb;42(2):66-75.
  • Costabel U, Bonella F. Treatment of pulmonary fibrosis. New substances and new interventions. Internist (Berl). 2011 Dec;52(12):1422-8.
  • Chlabicz S, Leszczynska K, Lukas W, Gualco L, Schito G, Naber KG. Uncomplicated lower urinary tract infections in females–clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy. Przegl Epidemiol. 2011;65(2):345-51.
  • Perepanova TS, Siniakova LA, Zaĭtsev AV, Kozlov RS, Shevelev AN, Gualco L, Achito G, Naber KG. Russian results of the international epidemiological study of clinical aspects and resistance to antimicrobial medicines of cystitis uropathogens in females (ARESC): significance of empiric therapy. Urologiia. 2011 Mar-Apr;(2):30-6.
  • Schito GC, Gualco L, Naber KG, Botto H, Palou J, Mazzei T, Marchese A. Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? J Chemother. 2010 Oct;22(5):345-54.
  • Rolando M, Bonini S, Aragona- P, Modorati GM, Barabino S. Lacrima. The Italian Register of Patients with Tear Dysfunction. TFOS (Tear Film and Ocular Surface), Florence 23-25 sept 2010. (poster).
  • Wagenlehner FM, Wagenlehner C, Savov O, Gualco L, Schito G, Naber KG. Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study. Urologe A. 2010 Feb;49(2):253-61.
  • Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009 Nov;34(5):407-13.
  • Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G; IFIGENIA study group. Lung function in idiopathic pulmonary fibrosis–extended analyses of the IFIGENIA trial. Respir Res. 2009 Oct 27.
  • Naber KG, Schito G, Botto et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008 Nov;54(5):1164-75.
  • Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, Capron F, Sardina M, Corvasce G, Lankhorst I; Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study group. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008 Mar;31(3):585-91. Epub 2007 Dec 5.
  • Equinozzi R, Robuschi M; Italian Investigational Study Group on Pholcodine in Acute Cough. Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study. Treat Respir Med. 2006;5(6):509-13.
  • Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 Nov 24;353(21):2229-42.
  • Lehmann HP,. Shortliffe EH. Information Technology Support of Clinical Research: An Introduction. December 2003, Volume 5, Issue 4, pp 415–419.